Session 1: SGLT2/Non-alcoholic fatty liver disease (NAFLD) Therapies

Date: Thursday, April 29th; 4:00 pm - 5:00 pm (eastern time)

Speakers: 

Sara Awad, MB BS, FRCPC Assistant Professor, Department of Medicine, Internal Medicine and Endocrinology & Metabolism, Associate Program Director Core Internal Medicine Program, Queen's University

Bikram Sidhu, MD FRCPC, Assistant Professor, Endocrinology and Diabetes, KHSC & Queen’s University.

Learning Objectives:

At the conclusion of this session, participants will be able to:

1. Identify the key uses of SGLT2 inhibitors in clinical practice
2. Integrate this therapy as a tool in addressing diabetic and nephrology cases in their practice

Speaker: Jennifer Flemming, MD, FRCPC, Associate Professor, Department of Medicine, Division of Gastroenterology, Queen’s University

Learning Objectives:

At the conclusion of this session, participants will be able to:

1. Discuss new therapies for addressing NAFLD
2. Assess and treat NAFLD using the latest therapeutic options